Home » Topics » BioWorld Science

BioWorld Science
RSS

PAF antagonist Y-24180 enters phase III

Aug. 23, 1996

Proventil HFA given FDA approval

Aug. 23, 1996

Hoechst Marion Roussel launches Allegra on U.S. market

Aug. 23, 1996

Further nitric oxide synthase inhibitors from Chugai

Aug. 23, 1996

The Wellcome Foundation claims nitric oxide synthase inhibitors

Aug. 23, 1996

Nitric oxide synthase inhibitors from Merck & Co.

Aug. 23, 1996

BASF reveals NMDA and AMPA antagonists

Aug. 23, 1996

UPF-596 described as a novel glutamate antagonist

Aug. 23, 1996

Nymox Pharmaceuticals present positive results from AD7C trial

Aug. 23, 1996

Study of senile plaques guide Alzheimer's development

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...